CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Candel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$8.21+0.02 (+0.24%)
Close on Oct 19, 2026
- Market cap
- $608.62M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
65.9%
50M of 77M shares
Institutional holders
138
40 new, 13 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 5 sales
Net sold $551.08K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong | 6,422,018 | 8.80% | 13G (passive) | Mar 31, 2026 |
| Paul B Manning | 5,790,999 | 7.90% | 13D (active) amendment | Dec 16, 2024 |
| BlackRock, Inc. | 4,834,899 | 6.60% | 13G (passive) | Jun 30, 2026 |
| FMR LLC | 3,923,599 | 9.30% | 13G (passive) | Dec 31, 2024 |
| Anders Hove | 2,580,517 | 5.20% | 13G (passive) | Jun 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CADL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 10,990,535 | 14.36% | $113.20M | +3,518 | 0.00% |
| Rtw Investments, LP | 6,422,018 | 8.39% | $66.15M | – | 0.56% |
| BlackRock, Inc. | 4,969,040 | 6.49% | $51.18M | +1,859,998 | 0.00% |
| State Street Corp | 3,549,823 | 4.64% | $36.56M | +2,731,265 | 0.00% |
| Acorn Capital Advisors, LLC | 3,497,948 | 4.57% | $36.03M | – | 9.83% |
| Portolan Capital Management, LLC | 3,490,398 | 4.56% | $35.95M | +596,073 | 1.35% |
| Saturn V Capital Management LP | 3,303,686 | 4.32% | $34.03M | +407,098 | 4.88% |
| Vanguard Capital Management LLC | 2,694,040 | 3.52% | $27.75M | +231,283 | 0.00% |
| Geode Capital Management, LLC | 1,571,021 | 2.05% | $16.18M | +535,586 | 0.00% |
| Millennium Management LLC | 1,093,905 | 1.43% | $11.27M | +33,819 | 0.00% |
| Halter Ferguson Financial Inc. | 772,461 | 1.01% | $7.96M | −131,590 | 1.29% |
| Northern Trust Corp | 492,465 | 0.64% | $5.07M | +169,311 | 0.00% |
| Kennedy Capital Management LLC | 488,291 | 0.64% | $5.03M | +395,666 | 0.09% |
| Vanguard Portfolio Management LLC | 437,150 | 0.57% | $4.50M | +168,901 | 0.00% |
| Vanguard Fiduciary Trust Co | 412,109 | 0.54% | $4.24M | +131,658 | 0.00% |
| Sands Capital Ventures, LLC | 405,837 | 0.53% | $4.18M | – | 0.68% |
| Goldman Sachs Group Inc | 305,216 | 0.40% | $3.14M | +77,695 | 0.00% |
| Marshall Wace, Llp | 300,641 | 0.39% | $3.10M | New | 0.00% |
| Bank Of America Corp /De/ | 278,944 | 0.36% | $2.87M | +231,542 | 0.00% |
| Susquehanna International Group, Llp | 227,939 | 0.30% | $2.35M | +114,966 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 138 | 50M | 65.9% | 40 / 63 | 24 / 13 | 10M | 3M |
| Q1 2026 | 114 | 43M | 56.8% | 39 / 40 | 22 / 8 | 23M | 1M |
| Q4 2025 | 84 | 24M | 30.9% | 13 / 32 | 19 / 10 | 2M | 1M |
| Q3 2025 | 81 | 23M | 29.6% | 15 / 27 | 23 / 12 | 1M | 2M |
| Q2 2025 | 78 | 23M | 30.1% | 16 / 40 | 14 / 20 | 5M | 3M |
| Q1 2025 | 82 | 21M | 27.7% | 24 / 39 | 12 / 12 | 6M | 3M |
| Q4 2024 | 71 | 18M | 23.5% | 22 / 32 | 10 / 2 | 13M | 0M |
| Q3 2024 | 52 | 7M | 8.8% | 16 / 16 | 10 / 8 | 2M | 1M |
| Q2 2024 | 45 | 6M | 7.8% | 31 / 9 | 4 / 6 | 3M | 1M |
| Q1 2024 | 20 | 4M | 4.9% | 4 / 6 | 5 / 5 | 0M | 0M |
| Q4 2023 | 22 | 4M | 5.3% | 4 / 5 | 6 / 2 | 0M | 1M |
| Q3 2023 | 20 | 5M | 6.9% | 2 / 5 | 5 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of CADL | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | 4,864,753 | 6.36% | $40.38M | 0.77% | May 31, 2026 |
| Fidelity Growth Company Fund | 2,111,072 | 2.76% | $17.52M | 0.02% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,024,039 | 2.65% | $20.85M | 0.19% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,968,034 | 2.57% | $20.27M | 0.00% | Jun 30, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 1,814,352 | 2.37% | $15.06M | 0.02% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,650,828 | 2.16% | $17.00M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 693,034 | 0.91% | $6.94M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 659,084 | 0.86% | $6.79M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 602,103 | 0.79% | $5.00M | 0.02% | May 31, 2026 |
| iShares Russell 2000 Growth ETF | 556,180 | 0.73% | $5.73M | 0.04% | Jun 30, 2026 |
| Fidelity Series Growth Company Fund | 555,760 | 0.73% | $4.61M | 0.02% | May 31, 2026 |
| iShares Biotechnology ETF | 410,502 | 0.54% | $4.23M | 0.05% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 264,530 | 0.35% | $2.72M | 0.10% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 233,623 | 0.31% | $1.94M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 211,492 | 0.28% | $2.18M | 0.14% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Paul Peter Tak | Chief Executive Officer, Director | 113,321 | 0.15% | Sep 11, 2026 |
| Seshu Tyagarajan | Chief Technology Officer | 76,865 | 0.10% | Aug 19, 2026 |
| Mark E. Sims | Chief Commercial Officer | – | – | Jul 8, 2026 |
| Francesca Barone | Chief Scientific Officer | 77,362 | 0.10% | Jul 1, 2026 |
| Charles Schoch | Chief Financial Officer | 43,391 | 0.06% | Jan 28, 2026 |
| William Garrett Nichols | Chief Medical Officer | 52,493 | 0.07% | Jan 28, 2026 |
| Martine Zimmermann | Director | – | – | Sep 10, 2026 |
| Joseph C. Papa | Director | 102,271 | 0.13% | Jul 1, 2026 |
| Paul B. Manning | Director | 5,748,279 | 7.51% | Jul 1, 2026 |
| Nicoletta Loggia | Director | 2,141 | 0.00% | Jul 1, 2026 |
| Maha Radhakrishnan | Director | – | – | Jun 24, 2026 |
| Renee Gaeta | Director | – | – | Jun 24, 2026 |
| Edward J. Benz JR | Director | – | – | Jun 24, 2026 |
| Diem Nguyen | Director | 10,000 | 0.01% | Jun 24, 2026 |
| Gary J. Nabel | Director | 5,353 | 0.01% | Jun 24, 2026 |
| Christopher Martell | Director | 698,863 | 0.91% | Jun 24, 2026 |
| Laura K. Aguilar | 10% owner | 4,574,440 | 5.98% | Feb 25, 2025 |
| Estuardo Aguilar-Cordova | 10% owner | 4,371,832 | 5.71% | Feb 25, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Paul Peter Tak Chief Executive Officer, Director | Sep 11, 2026 | Sale(10b5-1 plan) | −59,379 | $10.46 | $621.10K | 113,321 |
| Paul Peter Tak Chief Executive Officer, Director | Sep 10, 2026 | Sale(10b5-1 plan) | −220,866 | $11.50 | $2.54M | 172,700 |
| Paul Peter Tak Chief Executive Officer, Director | Sep 10, 2026 | Option exercise | +125,000 | $1.55 | $193.75K | 393,566 |
| Seshu Tyagarajan Chief Technology Officer | Aug 17, 2026 | Sale(10b5-1 plan) | −7,000 | $12.00 | $84.00K | 76,865 |
| Francesca Barone Chief Scientific Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −23,447 | $10.06 | $235.88K | 77,362 |
| Seshu Tyagarajan Chief Technology Officer | Jun 29, 2026 | Sale(10b5-1 plan) | −7,000 | $10.02 | $70.14K | 83,865 |
| Paul B. Manning Director | Feb 23, 2026 | Buy | +550,458 | $5.45 | $3.00M | 2,763,527 |
| William Garrett Nichols Chief Medical Officer | Jul 28, 2025 | Sale(10b5-1 plan) | −937 | $6.98 | $6.54K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Jul 28, 2025 | Option exercise | +937 | $1.29 | $1.21K | 53,430 |
| William Garrett Nichols Chief Medical Officer | Jun 30, 2025 | Sale(10b5-1 plan) | −781 | $5.04 | $3.94K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Jun 30, 2025 | Option exercise | +781 | $1.29 | $1.01K | 53,274 |
| Seshu Tyagarajan Chief Technology Officer | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 90,865 |
| Joseph C. Papa Director | Jun 25, 2025 | Award | +64,239 | $4.67 | $300.00K | 64,239 |
| Nicoletta Loggia Director | Jun 25, 2025 | Award | +2,141 | $4.67 | $10.00K | 2,141 |
| Gary J. Nabel Director | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 5,353 |
| Charles Schoch Chief Financial Officer | Jun 25, 2025 | Award | +5,353 | $4.67 | $25.00K | 43,391 |
| Christopher Martell Director | Jun 25, 2025 | Award | +111,349 | $4.67 | $520.00K | 111,349 |
| Paul Peter Tak Chief Executive Officer, Director | Jun 25, 2025 | Award | +42,826 | $4.67 | $200.00K | 268,566 |
| Paul B. Manning Director | Jun 25, 2025 | Award | +1,070,663 | $4.67 | $5.00M | 2,213,069 |
| Francesca Barone Chief Scientific Officer | Jun 25, 2025 | Award | +4,282 | $4.67 | $20.00K | 100,809 |
| Paul Peter Tak Chief Executive Officer, Director | Mar 19, 2025 | Sale(10b5-1 plan) | −400 | $9.00 | $3.60K | 225,740 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −45,316 | $8.76 | $396.97K | 52,493 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Option exercise | +13,905 | $1.29 | $17.94K | 97,809 |
| William Garrett Nichols Chief Medical Officer | Mar 18, 2025 | Option exercise | +4,584 | $3.75 | $17.19K | 83,904 |
| Paul Peter Tak Chief Executive Officer, Director | Mar 18, 2025 | Sale(10b5-1 plan) | −25,772 | $8.77 | $226.02K | 226,140 |
| Francesca Barone Chief Scientific Officer | Mar 18, 2025 | Sale(10b5-1 plan) | −32,146 | $8.76 | $281.60K | 96,527 |
| Francesca Barone Chief Scientific Officer | Mar 18, 2025 | Option exercise | +18,000 | $1.55 | $27.90K | 128,673 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Option exercise | +20,000 | $1.29 | $25.80K | 116,790 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Sale(10b5-1 plan) | −31,278 | $8.82 | $275.87K | 85,512 |
| Charles Schoch See Remarks | Mar 17, 2025 | Sale(10b5-1 plan) | −5,000 | $8.83 | $44.15K | 38,038 |
| Seshu Tyagarajan Chief Technology Officer | Mar 17, 2025 | Sale(10b5-1 plan) | −31,278 | $8.82 | $275.87K | 85,512 |
| Estuardo Aguilar-Cordova 10% owner | Feb 21, 2025 | Returned to company | −10,582 | $12.02 | $127.20K | 120,861 |
| Estuardo Aguilar-Cordova 10% owner | Feb 21, 2025 | Returned to company | −10,583 | $12.02 | $127.21K | 162,929 |
| Estuardo Aguilar-Cordova 10% owner | Feb 10, 2025 | Returned to company | −31,335 | $8.61 | $269.79K | 60,000 |
| Seshu Tyagarajan Chief Technology Officer | Jan 15, 2025 | Sale | −14,322 | $7.23 | $103.55K | 96,790 |
| Paul Peter Tak Chief Executive Officer, Director | Jan 15, 2025 | Sale | −21,704 | $7.23 | $156.92K | 251,912 |
| Francesca Barone Chief Scientific Officer | Jan 15, 2025 | Sale | −13,534 | $7.23 | $97.85K | 110,673 |
| Charles Schoch See Remarks | Jan 15, 2025 | Sale | −9,511 | $7.23 | $68.76K | 43,038 |
| William Garrett Nichols Chief Medical Officer | Jan 15, 2025 | Sale | −10,428 | $7.23 | $75.39K | 79,320 |
| Seshu Tyagarajan Chief Technology Officer | Jan 8, 2025 | Sale | −14,545 | $8.22 | $119.56K | 111,112 |
| Charles Schoch See Remarks | Jan 8, 2025 | Sale | −9,971 | $8.22 | $81.96K | 52,549 |
| William Garrett Nichols Chief Medical Officer | Jan 8, 2025 | Sale | −10,799 | $8.22 | $88.77K | 89,748 |
| Francesca Barone Chief Scientific Officer | Jan 8, 2025 | Sale | −13,673 | $8.22 | $112.39K | 124,207 |
| Paul Peter Tak Chief Executive Officer, Director | Jan 8, 2025 | Sale | −21,172 | $8.22 | $174.03K | 273,616 |
| Laura K. Aguilar 10% owner | Dec 27, 2024 | Returned to company | −50,000 | $8.85 | $442.50K | 131,443 |
| Laura K. Aguilar 10% owner | Dec 27, 2024 | Returned to company | −50,000 | $8.85 | $442.50K | 173,512 |
| Laura K. Aguilar 10% owner | Dec 26, 2024 | Returned to company | −50,000 | $9.01 | $450.50K | 181,443 |
| Laura K. Aguilar 10% owner | Dec 26, 2024 | Returned to company | −50,000 | $9.01 | $450.50K | 223,512 |
| Laura K. Aguilar 10% owner | Dec 24, 2024 | Returned to company | −50,000 | $8.82 | $441.00K | 231,443 |
| Laura K. Aguilar 10% owner | Dec 24, 2024 | Returned to company | +50,000 | $8.82 | $441.00K | 273,512 |
| Laura K. Aguilar 10% owner | Dec 23, 2024 | Returned to company | −50,000 | $8.52 | $426.00K | 281,443 |
| Laura K. Aguilar 10% owner | Dec 23, 2024 | Returned to company | −50,000 | $8.52 | $426.00K | 323,512 |
| Laura K. Aguilar 10% owner | Dec 20, 2024 | Returned to company | −100,000 | $9.00 | $900.00K | 373,512 |
| Laura K. Aguilar 10% owner | Dec 20, 2024 | Returned to company | −100,000 | $9.00 | $900.00K | 331,443 |
| Paul B. Manning Director | Dec 16, 2024 | Buy | +750,000 | $6.00 | $4.50M | 1,303,752 |
| Paul B. Manning Director | Dec 16, 2024 | Buy | +500,000 | $6.00 | $3.00M | 1,142,406 |
| Estuardo Aguilar-Cordova 10% owner | Dec 12, 2024 | Returned to company | −200,000 | $10.04 | $2.01M | 473,512 |
| Estuardo Aguilar-Cordova 10% owner | Dec 12, 2024 | Returned to company | −200,000 | $10.04 | $2.01M | 431,443 |
| Estuardo Aguilar-Cordova 10% owner | Dec 11, 2024 | Returned to company | −200,000 | $8.53 | $1.71M | 631,443 |
| Estuardo Aguilar-Cordova 10% owner | Dec 11, 2024 | Returned to company | −200,000 | $8.53 | $1.71M | 673,512 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Peter Tak Paul Director, Officer | Sep 10, 2026 | 280,245 | $3.41M | Sep 10, 2026 | Exercise of Stock Options |
| Tyagarajan Seshu Officer | Aug 17, 2026 | 7,000 | $82.04K | Aug 17, 2026 | Restricted Stock Units |
| Barone Francesca Officer | Jun 29, 2026 | 23,447 | $229.55K | Jun 29, 2026 | Restricted Stock Units |
| P. Tyagarajan Seshu Officer | Jun 29, 2026 | 7,000 | $68.53K | Jun 29, 2026 | Restricted Stock Units |
| Garrett Nichols William Officer | Jun 30, 2025 | 3,593 | $17.61K | Jun 30, 2025 | Exercise of Stock Options |
| Peter Tak Paul Director, Officer | Mar 18, 2025 | 74,106 | $654.36K | Mar 18, 2025 | Open Market Purchase |
| Barone Francesca Officer | Mar 18, 2025 | 32,146 | $283.85K | Mar 18, 2025 | Exercise of Stock Options |
| Garrett Nichols William Officer | Mar 18, 2025 | 45,316 | $400.14K | Mar 18, 2025 | Exercise of Stock Options |
| Tyagarajan Seshu Officer | Mar 17, 2025 | 31,278 | $273.68K | Mar 17, 2025 | Exercise of Stock Options |
| Schoch Charles Officer | Mar 17, 2025 | 5,000 | $43.75K | Mar 17, 2025 | Open Market Purchase |
| Paul Peter Tak Officer, Director | Jan 15, 2025 | 19,970 | $156.56K | Jan 15, 2025 | RSU Award |
| Charles Schoch Officer | Jan 15, 2025 | 8,751 | $68.61K | Jan 15, 2025 | RSU Award |
| Francesca Barone Officer | Jan 15, 2025 | 12,452 | $97.62K | Jan 15, 2025 | RSU Award |
| Seshu Tyagarajan Officer | Jan 15, 2025 | 13,177 | $103.31K | Jan 15, 2025 | RSU Award |
| William Garrett Nichols Officer | Jan 15, 2025 | 9,564 | $75.22K | Jan 15, 2025 | RSU Award |